NSCLC Videos

According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that continuing pemetrexed maintenance therapy is advantageous for patients treated with the KEYNOTE-189 regimen.

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that surgical approaches have a limited role in the treatment of patients with stage 3 non-small cell lung cancer.

Joshua Sabari, MD, discussed exploratory analysis results from the phase 3 MARIPOSA study evaluating the impact of amivantamab dose interruptions, as presented at the European Lung Cancer Congress 2024.

Alexander Spira, MD, PhD, FACP, discussed post-progression results from the phase 3 MARIPOSA-2 trial, as presented at the European Lung Cancer Congress 2024.

Joshua Sabari, MD, discussed post-progression secondary end points from the phase 3 PAPILLON trial evaluating amivantamab plus chemotherapy among patients with advanced EGFR-mutated non-small cell lung cancer, as presented at the European...

Christian Rolfo, MD, PhD, Icahn School of Medicine, Mount Sinai Medical Center, New York, New York, discusses results from the phase 2 VISION trial.

At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Lyudmila Bazhenova, MD, discussed developments and advances in the management of BRAF-mutated NSCLC.

At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Natasha Leighl, MD, FRCPC, FASCO, discussed the primacy of front-line checkpoint inhibitors in non-small cell lung cancer.